ArticleInfection and immunity2002
Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.
Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 91 citations in OpenAlex.
- Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.Infection and immunity · 2006Trial
- Conserved antigens for enteric vaccines.Vaccine · 2025Review
- A First in Human Clinical Trial Assessing the Safety and Immunogenicity of Two Intradermally Delivered EnterotoxigenicMicroorganisms · 2023Article
- Establishment of isotype-switched, antigen-specific B cells in multiple mucosal tissues using non-mucosal immunization.NPJ vaccines · 2023Article
- Protective efficacy of a novel multivalent vaccine in the prevention of diarrhea induced by enterotoxigenicJournal of veterinary science · 2022Article
- Immunological Evidence of Variation in Exposure and Immune Response toFrontiers in immunology · 2022Article
- Article
- Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4Mucosal immunology · 2018Article
- Pathogen-induced secretory diarrhea and its prevention.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Review
- Comparative Adjuvant Effects of Type II Heat-Labile Enterotoxins in Combination with Two Different Candidate Ricin Toxin Vaccine Antigens.Clinical and vaccine immunology : CVI · 2015Article
- Current Progress in Developing Subunit Vaccines against Enterotoxigenic Escherichia coli-Associated Diarrhea.Clinical and vaccine immunology : CVI · 2015Review
- Antigen-specific memory B-cell responses to enterotoxigenic Escherichia coli infection in Bangladeshi adults.PLoS neglected tropical diseases · 2014Article
- Immunogenicity of a fusion protein comprising coli surface antigen 3 and labile B subunit of enterotoxigenic Escherichia coli.Iranian biomedical journal · 2014Article
- Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant.Human vaccines & immunotherapeutics · 2012Article
- Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.Clinical and vaccine immunology : CVI · 2012Article
- Serum antibodies protect against intraperitoneal challenge with enterotoxigenic Escherichia coli.Journal of biomedicine & biotechnology · 2011Article
- Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.Vaccine · 2010Article
- Toxin-mediated effects on the innate mucosal defenses: implications for enteric vaccines.Infection and immunity · 2009Review
- Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Enterotoxigenic Escherichia coli (ETEC) diarrheal disease is a worldwide problem that may be addressed by transcutaneous delivery of a vaccine. In several human settings, protective immunity has been associated with immune responses to E. coli colonization factors and to the heat-labile toxin that induces the diarrhea. In this set of animal studies, transcutaneous immunization (TCI) using recombinant colonization factor CS6 and cholera toxin (CT) or heat-labile enterotoxin (LT) as the adjuvant induced immunoglobulin G (IgG) and IgA anti-CS6 responses in sera and stools and antibody responses that recognized CS6 antigen in its native configuration. The antitoxin immunity induced by TCI was also shown to protect against enteric toxin challenge. Although immunization with LT via the skin induced mucosal secretory IgA responses to LT, protection could also be achieved by intravenous injection of the immune sera. Finally, a malaria vaccine antigen, merzoite surface protein 1(42) administered with CT as the adjuvant, induced both merzoite surface protein antibodies and T-cell responses while conferring protective antitoxin immunity, suggesting that both antiparasitic activity and antidiarrheal activity can be obtained with a single vaccine formulation. Overall, our results demonstrate that relevant colonization factor and antitoxin immunity can be induced by TCI and suggest that an ETEC traveler's diarrhea vaccine could be delivered by using a patch.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.